Investigational drug · Phase 2
ENV-101
Also called: taladegib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "ENV-101"
First trial start
2024
Nov 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENV-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis
- Progressive Fibrosing Interstitial Lung Disease
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "ENV-101" as an intervention, largest first.
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)Pivotal-lookingCompleted
Endeavor Biomedicines, Inc.Industry
NCT06422884 · 213 participants · Start Nov 15, 2024 · Primary completion Aug 21, 2026
Drug: ENV-101; Placebo · For: Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease
Sites: Quilmes, Argentina; Buenos Aires, Argentina; Mendoza, Argentina · 78 sites in all
Endeavor Biomedicines, Inc.Industry
NCT07454291 · 57 participants (planned) · Start Apr 28, 2026 · Primary completion Oct 2026
Drug: taladegib; nintedanib and 2 more · For: Idiopathic Pulmonary Fibrosis
Sites: Brisbane, Australia; Melbourne, Australia
Endeavor Biomedicines, Inc.Industry
NCT04968574 · 41 participants · Start Aug 26, 2021 · Primary completion Nov 30, 2023
Drug: taladegib; placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Liverpool, Australia; Benowa, Australia; Box Hill, Australia · 24 sites in all
Endeavor Biomedicines, Inc.Industry
NCT05817240 · 21 participants · Start May 3, 2023 · Primary completion Jun 11, 2023
Drug: taladegib; nintedanib · For: Idiopathic Pulmonary Fibrosis
Sites: Adelaide, Australia
Endeavor Biomedicines, Inc.Industry
NCT05199584 · 20 participants · Start May 24, 2022 · Primary completion Feb 20, 2024
Drug: ENV-101 (taladegib) · For: Solid Tumors With PTCH1 Loss-of-function Mutations
Sites: Los Angeles, California; Santa Rosa, California; Tampa, Florida · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.
Glasspool R, Blagden SP, Lockley M, et al. · Invest New Drugs 2026
- Computational Mapping of Hedgehog Pathway Kinase Module Predicts Node-Specific Craniofacial Phenotypes.
Gramatikoff K, Stoykov M, Hörmann K, et al. · Genes (Basel) 2026
- Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.
Maher TM, Goldin JG, Hood J, et al. · Lancet Respir Med 2025
- Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review.
Markota Cagalj A, Glibo M, Karin-Kujundzic V, et al. · J Drug Target 2025
- A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Azaro A, Massard C, Tap WD, et al. · Invest New Drugs 2021
- Taladegib controls early chondrocyte hypertrophy via inhibiting smoothened/Gli1 pathway.
Luan J, Tao H, Su Y · Am J Transl Res 2020
Also in development for Idiopathic Pulmonary Fibrosis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.